Cancer Immunotherapy Scientific Poster Session

Cancer Immunotherapy Update

Slides, Abstracts, and Posters

The Center for Healthcare Education and our expert faculty have selected the following posters and abstracts in the areas of cancer immunotherapy from the American Society of Hematology (ASH) 2007 annual meeting, held on December 9, 2007, in Atlanta, Georgia. These abstracts and posters, previously presented or published, provide critical new data and serve as the foundation for discussion of new evidence in the management of cancer. We have included each poster along with PowerPoint slides for you to view and/or download.

We welcome you to view the information for educational purposes.

CANCER IMMUNOTHERAPY

abstract
Initial Resuits From an International Study in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma to Confirm the Activity, Safety, and Criteria for Predicting Response to Lenalidomide Monotherapy
Czuczman M, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Patel H, Vafai D, Wiernik PH, Ervin-Haynes A, Pietronigro D, Zeldis JB, Witzig TE.

abstract
Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin's Lymphoma
Leonard JP, Shuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Goldenberg DM.

poster slides
Active Immunotherapy with Mitumprotimut-T (Specifid, FavId, Id-KLH) Following Rituximab Induction in Patients with Follicular B-cell Lymphoma: Progression-Free Survival at 4-year Follow-Up
Koc ON, et al.

poster slides
Continued Late Conversion to Complete Remission and Durability of Remission in Patients with B-cell Follicular Lymphoma Treated with Rituximab Followed by Mitumprotimut-T (Specifid, FavId) Immunotherapy
Koc ON, et al.

poster slides
Therapeutic Lymphoma Idiotype Vaccine Generated in Insect Cells Results in Mannose Receptor Targeting and Enhanced Immune Activation
Betting DJ, et al.

poster slides
FCgRIIIA Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T (Specifid, Id-KLH, FavId)
Maloney DG, Pender B, McCarthy E, Gold DP.

ACS (12)

diabetes (1)

DVT (1)

heart failure (8)

hospital-acquired infections (2)

IGF-1 deficiency (1)

PE (1)

Renal Disease (1)

thrombosis (15)

VTE (1)

anesthesiology (6)

cardiology (14)

emergency medicine (13)

hematology & oncology (4)

infectious disease (2)

nephrology (1)

orthopaedic surgery (5)

pediatric endocrinology (1)

Cecilia Linde, PhD, MD (1)

Jack E. Ansell, MD (3)

Carlos A. Carmargo, MD, Dr.PH (1)

Fred D. Cushner, MD (1)

Germano Di Sciascio, MD (4)

Deborah B. Diercks, MD, FACEP (3)

Charles Louis Emerman, MD (3)

Jay L. Falk, MD (1)

Richard J. Friedman, MD, FRCSC (1)

C. Michael Gibson, MS, MD (3)

Patrick A. Gladding, MD (1)

Paul A. Gurbel, MD (2)

Christian W. Hamm, MD, FESC, FACC (1)

James W. Hoekstra, MD (4)

Judd E. Hollander, MD (4)

Michael H. Huo, MD (1)

Preeti Jois-Bilowich, MD (1)

J. Douglas Kirk, MD (1)

Peter R. Kowey, MD (1)

Stephen A. Mayer, MD (3)

David J. Moliterno, MD, MPH (2)

James F. Neunschwander II, MD (1)

H. Bryant Nguyen, MS, MD (1)

Richard M. Nowak, MD, MBA (1)

E. Magnus Ohman, MB, FRCPI, FES, FACC (2)

Arthur M. Pancioli, MD (3)

Javad Parvizi, MD, FRCS (1)

W. Frank Peacock IV, MD, FACEP (4)

Eric D. Peterson, MD, MPH (2)

Duane S. Pinto, MD (0)

Jeffrey J. Popma, MD, FSCAI (1)

Ivan C. Rokos, MD, FACEP (3)

Germano Di Sciascio, MD, FACC, FESC (1)

Nathan I. Shapiro, MD, MPH (1)

Peter Sleight, MD (1)

Alan B. Storrow, MD (3)

Richard L. Summers, MD (1)

Mark Turco, MD, FACC, FSCAI (2)

Alexander G. G. Turpie, MD, FRCP, FRCPC (3)

Marvin A. Wayne, MD (1)

Stephen D. Wiviott, MD (1)

Clinical Conference Coverage